#USA #Atlanta #Airway Therapeutics #Zelpultide Alfa #Bronchopulmonary Dysplasia

Airway Therapeutics Secures NIH Grant

Airway Therapeutics, a pioneering clinical biopharmaceutical company, has achieved a significant milestone by receiving a $1.9 million grant from the National Institutes of Health (NIH). This funding will support its ongoing Phase 2b clinical trial that investigates zelpultide alfa for preventing bronchopulmonary dysplasia (BPD) in very preterm infants. The award, granted by the National Heart, Lung, and Blood Institute under the Small Business Innovation Research (SBIR) program, will provide much-needed non-dilutive capital to bolster their late-stage clinical development efforts.

This funding follows the encouraging results seen in a previous Phase 1b study that demonstrated favorable safety and tolerability for zelpultide alfa. Moreover, the trial is also making progress in Europe, Argentina, and Israel, paving the way for inclusive global research on this vital therapy. Airway Therapeutics aims to leverage this NIH support to address a significant medical need, as current preventive therapies for BPD remain nonexistent.

The Importance of BPD

Bronchopulmonary dysplasia is a serious chronic lung disease that primarily affects very preterm infants. These vulnerable infants face serious risks due to underdeveloped pulmonary defense mechanisms, such as surfactant protein D (SP-D), which is crucial for maintaining lung function by regulating inflammation and supporting the innate immune defense. The development and application of zelpultide alfa, which acts as a recombinant human SP-D therapy, represents a groundbreaking advancement aimed at restoring these critical functions in infants diagnosed with BPD.

Dr. Marc Salzberg, the CEO of Airway Therapeutics, spoke about the significance of the NIH award, stating, “This recognition is a testament to the scientific foundation of our program and highlights the urgent need for innovative preventive measures in combating BPD.” His statement emphasizes the company’s commitment to advancing a biologic therapy that addresses this significant unmet medical need among vulnerable infants.

Understanding Zelpultide Alfa

Zelpultide alfa represents a new class of biologic therapies, specifically engineered to mimic SP-D's natural features and optimize its function. It employs advanced cell line technology to ensure a proper quaternary structure and biological efficacy, focusing on three essential actions: 1) modulating immune responses to decrease excessive inflammation, 2) enhancing recognition and clearance of pathogens, and 3) maintaining surfactant homeostasis crucial for lung function. This versatile therapeutic candidate is developing a pathway not only for infants but also for adults suffering from acute and chronic respiratory conditions.

Currently, zelpultide alfa is in the late-stage clinical development phase to prevent BPD, following promising results from earlier trials that showcased its safety. By participating in the current Phase 2b study, researchers will evaluate the treatment’s efficacy against the standard of care in high-risk preterm neonates, gauging its potential for effectively reducing both the incidence and severity of BPD.

Looking Ahead

Airway Therapeutics is striving to redefine how respiratory, inflammatory, and infectious diseases are approached. As it plots its future clinical pathways, the company is keen on leveraging the positive momentum created by the NIH funding approval. In doing so, it aims to bridge the gap in preventative healthcare, especially for the most vulnerable populations, while continuing to explore wider applications across various age groups and medical conditions.

As the Phase 2b/3 clinical trial unfolds, all eyes will be on Airway Therapeutics and the impact of zelpultide alfa on the futures of countless preterm infants struggling with BPD. The ongoing commitment to develop innovative therapies will not only benefit these young patients but will also shape future approaches to respiratory health in broader adult populations. With the resolution of BPD as the first milestone, this trailblazing initiative heralds a promising future for biologic therapies in respiratory medicine.

For more information about Airway Therapeutics and its innovative projects, visit Airway Therapeutics.